What Is TRH? Benefits, Research & Safety
A hypothalamic tripeptide that regulates thyroid function and has diverse effects on the brain and metabolism.
UK summary: Endogenous hypothalamic hormone. Synthetic TRH (protirelin) is used clinically for thyroid-axis testing; not appropriate for wellness self-administration.
Quick Facts
Overview
TRH — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous hypothalamic hormone. Synthetic TRH (protirelin) is used clinically for thyroid-axis testing; not appropriate for wellness self-administration.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Protirelin available for diagnostic use.
- EU: Available for diagnostic purposes in some countries.
- Notes: TRH (protirelin) is approved for diagnostic testing of pituitary-thyroid axis function. Therapeutic applications are limited. Some TRH analogues are approved in Japan for neurological conditions.
05Approved medical uses
- TRH (protirelin) for thyroid-axis stimulation testing — hospital use.
06Unapproved / promotional claims
- TRH treats hypothyroidism.
- TRH boosts metabolism for fat loss.
07Common internet claims
- Marketed by some research-peptide vendors for thyroid 'support' or 'metabolic boost'.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “TRH treats hypothyroidism” | E | No | High | Hypothyroidism is treated with thyroid hormones (levothyroxine etc), not with TRH. TRH is for diagnostic testing. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Transient flushing, urgency, hypertension during diagnostic test.
- Not appropriate for self-administration; underlying thyroid dysfunction needs investigation.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Protirelin available for diagnostic use.
14EU legal position
Available for diagnostic purposes in some countries.
15What this page cannot tell you
- Whether self-administered TRH improves any clinical outcome.
- Whether grey-market TRH products contain the labelled compound.
16Last reviewed
17Citation quality score
18Research gaps
- Therapeutic use of TRH was largely superseded by direct thyroid hormone replacement.
19Safer alternatives / established care pathways
- NHS GP / endocrinology workup for suspected hypothyroidism — TSH, free T4, antibodies.
- Licensed levothyroxine for confirmed hypothyroidism.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What thyroid investigations and licensed treatments are appropriate for my symptoms?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Diagnostic utility in pituitary-thyroid assessment
- 2Potential antidepressant effects (research)
- 3Possible neuroprotective properties
- 4Arousal and alertness enhancement
- 5Thermogenic effects
- 6TRH analogues approved for some neurological conditions (Japan)
Claim vs Evidence
How popular claims about TRH stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “TRH treats hypothyroidism” | E | No | High | Hypothyroidism is treated with thyroid hormones (levothyroxine etc), not with TRH. TRH is for diagnostic testing. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 200-500 mcg IV for diagnostic TRH stimulation test |
| Frequency | Single dose for diagnostic test |
| Duration | Acute diagnostic procedure |
| Notes | TRH (protirelin) is used clinically for diagnostic testing. Therapeutic applications are limited by very short half-life. TRH analogues have been developed with improved stability for potential neurological applications. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous (diagnostic testing)
- Some oral TRH analogues studied
| Half-Life | Stability |
|---|---|
| Approximately 5 minutes (very short) | Rapidly degraded by serum enzymes; requires IV administration for diagnostic use |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea
- Flushing
- Urge to urinate
- Light-headedness
- Transient blood pressure changes
- Strange taste in mouth
Rare Risks & Concerns
- Blood pressure spikes in susceptible individuals
- Rare bronchospasm
- Pituitary apoplexy in patients with pituitary tumours (rare)
Contraindications
- Known hypersensitivity
- Uncontrolled hypertension
- Recent myocardial infarction
- Asthma (relative)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Protirelin available for diagnostic use.
🇪🇺 European Union
Available for diagnostic purposes in some countries.
Clinical Studies Summary
Drug treatment for spinal muscular atrophy types II and III.
Nusinersen improves motor function in SMA type II, based on moderate-certainty evidence. Creatine, gabapentin, hydroxyurea, phenylbutyrate, valproic acid and the combination of valproic acid and ALC probably have no clinically important effect on motor function in SMA types II or III (or both) based on low-certainty evidence, and olesoxime and somatropin may also have little to no clinically important effect but evid…
Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease.
Prenatal TRH in addition to corticosteroids, given to women at risk of preterm birth, does not improve infant outcomes and can cause maternal side effects. Therefore, all tasks relating to these studies (assessment of eligibility for inclusion, assessment of risk of bias, and data extraction) were carried out by other members of the review team who were not directly involved in the trials.
Targeting the brain-gut-prostate axis in chronic prostatitis: mechanisms and therapeutics.
, Th17/Treg imbalance) are explored, alongside innovative therapies such as microbiome modulation, neural interventions, and immune regulation. This holistic paradigm not only provides new mechanistic insights but also offers promising avenues for personalized management and translational research in CP/CPPS, potentially overcoming current therapeutic bottlenecks.
Early tumor-related hemorrhage after stereotactic radiosurgery of brain metastases: Systematic review of reported cases.
Early TRH is very rare, but potentially life-threatening complication of SRS for BM; thus, its risk (while extremely low) and possible consequences should be discussed at the time of obtaining informed consent.
Hypothalamic-pituitary-thyroid (HPT) axis functioning in anxiety disorders. A systematic review.
The findings resonate well with clinical recommendations to routinely screen for thyroid disorders in patients with anxiety disorders, and with what is known from basic research about thyroid-brain interactions. The results of the risk of bias assessment underscore the importance of further high-quality experimental and longitudinal epidemiological research.
Thyroid adverse effects of psychotropic drugs: a review.
Patients receiving lithium, phenothiazines, and tricyclic antidepressants TCA should be closely monitored for the development of thyroid function abnormalities. Only patients at risk for developing thyroid function abnormalities should be monitored when they receive typical and/or atypical antipsychotic drugs, nontricyclic antidepressant drugs, and carbamazepine.
Registered Trials & Regulatory Status
17 of 21 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding
Status: Not Yet Recruiting · 120 participants · Bahcesehir Cyprus University
Conditions: Mitochondrial Degradation, Autophagy, Fasting
The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD)
Status: Not Yet Recruiting · 26 participants · Universiti Kebangsaan Malaysia Medical Centre
Conditions: Alcoholic Fatty Liver Disease
Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases
Status: Not Yet Recruiting · 30 participants · Affiliated Hospital of Nantong University
Conditions: Diabetic Keratopathy
Shoulder Denervation for Post Mastectomy Irradiation Shoulder Pain
Status: Recruiting · 60 participants · National Cancer Institute, Egypt
Conditions: Breast Cancer
LIRRH Trial for the Right-sided Colon Cancer
Status: Recruiting · 120 participants · Chaoxi Zhou
Conditions: Ascending Colon Cancer, Proximal Transverse Colon Cancer
Comparison of Pulsed and Thermal Radiofrequency for Trigeminal Neuralgia
Status: Recruiting · 60 participants · Zagazig University
Conditions: Trigeminal Neuralgia
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Status: Recruiting · 300 participants · Centre Hospitalier Universitaire de Liege
Conditions: Neuromuscular Diseases, Obesity (Disorder), Myotonic Dystrophy 1
The Alkmaar MLPTI Cohort Study: Outcomes at 9 Years
Status: Active Not Recruiting · 153 participants · Noordwest Ziekenhuisgroep
Conditions: Preterm Birth, Developmental Delay, Growth Delay
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
Status: Recruiting · 568 participants · Zhejiang University
Conditions: Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Time Restricted Eating for the Treatment of Type 2 Diabetes
Status: Completed · 75 participants · University of Illinois at Chicago
Conditions: Diabetes Mellitus, Type 2, Obesity
Effects of TRF on Obese Patients With CKD Stage 3-4
Status: Completed · 28 participants · Guangdong Provincial Hospital of Traditional Chinese Medicine
Conditions: Time Restricted Feeding, Renal Insufficiency, Chronic, Obesity
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
Status: Withdrawn · Memorial Sloan Kettering Cancer Center
Conditions: Thyroid Cancer
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for TRH?
Source research-grade TRH from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about TRH
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What thyroid investigations and licensed treatments are appropriate for my symptoms?